Has low-dose intracoronary thrombolysis gained ground in primary percutaneous intervention?

IF 4.7 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2025-10-01 Epub Date: 2022-11-04 DOI:10.1177/00033197221138725

Rasha Kaddoura, Mohamed Izham Mohamed Ibrahim, Abdul Rahman Arabi

引用次数: 0

Abstract

Reducing thrombus burden would improve patient's outcomes. Low-dose intracoronary thrombolytic agent administration has been considered to improve myocardial microcirculation, cardiac function, and major adverse cardiovascular events in patients presenting with ST-segment elevation myocardial infarction and high thrombus burden. This paper discusses published meta-analyses on intracoronary thrombolysis in primary percutaneous intervention.

查看原文本刊更多论文

低剂量冠状动脉内溶栓是否已在初级经皮介入治疗中占据优势？

减少血栓负担将改善患者的预后。小剂量冠状动脉内溶栓药物被认为可以改善ST段抬高型心肌梗死和高血栓负荷患者的心肌微循环、心脏功能和主要不良心血管事件。本文讨论了已发表的关于初级经皮介入治疗中冠状动脉内溶栓的荟萃分析。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464

期刊介绍： ACS Applied Bio Materials is an interdisciplinary journal publishing original research covering all aspects of biomaterials and biointerfaces including and beyond the traditional biosensing, biomedical and therapeutic applications. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrates knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important bio applications. The journal is specifically interested in work that addresses the relationship between structure and function and assesses the stability and degradation of materials under relevant environmental and biological conditions.